-

11:06:29 AM

CSLLY Stock News

CSLLY - CSL Ltd.

01/18/22 1:08 AM

OTC : CSLLY, GNHAY

CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly

RHEA-AI

neutral

01/18/22 1:05 AM

OTC : GNHAY, CSLLY

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.

Regulatory News:. CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd., a global specialty pharmaceutical company with...

RHEA-AI

neutral

12/15/21 7:33 AM

OTC, Nasdaq : CSLLY, QURE

CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B

Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its request for an accelerated assessment of the

RHEA-AI

very positive

12/15/21 7:30 AM

OTC : CSLLY

EMA Grants Accelerated Assessment for CSL Behring's Haemophilia B Gene Therapy

CSL Behring today announced that the European Medicines Agency (EMA) has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application (MAA). Etranacogene dezaparvovec is an

RHEA-AI

very positive

12/14/21 12:44 AM

OTC : GNHAY, CSLLY

acquisition

CSL Limited announces tender offer to acquire Vifor Pharma Ltd

Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US $179.25 per share Offer equivalent to CHF167 per share 1 Proposed ordinary dividend expected to be declared at AGM of 26 April 2022 of CHF 2 to be paid in addition This offer represents A premium of 61% to Vifor Pharma’ s unaffected closing share...

RHEA-AI

positive

12/07/21 1:00 PM

OTC : CSLLY

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the relative effectiveness of FLUAD ® (Influenza Vaccine, Adjuvanted), its adjuvanted trivalent vaccine

RHEA-AI

neutral

11/23/21 8:30 AM

OTC : CSLLY

fda approval

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. 1 As the first-ever adjuvanted, cell-based influenza vaccine, AUDENZ™

RHEA-AI

very positive

10/26/21 7:05 AM

OTC : CSLLY

CSL Plasma Opens 300th Plasma Donation Center in United States

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced the opening of its 300 th U.S. plasma center, which is located in Greenacres, Florida. CSL Plasma is one of the world's largest collectors of

RHEA-AI

neutral

10/19/21 7:30 AM

OTC : CSLLY

Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines. These analyses from a

RHEA-AI

negative

10/18/21 8:30 PM

OTC : CSLLY

clinical trial

Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day

During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel pipeline that spans six therapeutic areas (immunology, hematology, respiratory, cardiovascular

RHEA-AI

positive